Vmars Biopharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 Cr
as on 12-12-2024
- Revenue 3751.44%
(FY 2023)
- Profit 3509.34%
(FY 2023)
- Ebitda 770.84%
(FY 2023)
- Net Worth 1952.95%
(FY 2023)
- Total Assets 304.95%
(FY 2023)
About Vmars Biopharma
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.50 Cr.
Sujith Naranthatta, Santhekasalagere Mahesha, Senthilkumar Murugesan, and Two other members serve as directors at the Company.
- CIN/LLPIN
U72900KA2020PTC141983
- Company No.
141983
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Vmars Biopharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujith Naranthatta  | Managing Director | 02-Aug-2021 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Santhekasalagere Mahesha | Director | 02-Aug-2021 | Current |
| Senthilkumar Murugesan | Director | 02-Aug-2021 | Current |
| Mambully Milash | Director | 02-Aug-2021 | Current |
| Varuni Ginigeri | Director | 28-Mar-2024 | Current |
Financial Performance of Vmars Biopharma.
Vmars Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 3751.44% increase. The company also saw a substantial improvement in profitability, with a 3509.34% increase in profit. The company's net worth Soared by an impressive increase of 1952.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vmars Biopharma?
Unlock access to Vmars Biopharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Nov 2022 | ₹2.50 Cr | Open |
How Many Employees Work at Vmars Biopharma?
Vmars Biopharma has a workforce of 28 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vmars Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vmars Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
